#Pirtobrutinib
LightNews LightNews
gmj-georgia.bsky.social
Pirtobrutinib-venetoclax-rituximab triple therapy demonstrates superior progression-free survival versus dual therapy in resistant CLL.

https://news.gmj.ge/briefs/pirtobrutinib-significantly-extends-survival-in-heavily-pretreated-cll-patients/
Pirtobrutinib Significantly Extends Survival in Heavily Pretreated CLL Patients
Pirtobrutinib-venetoclax-rituximab triple therapy demonstrates superior progression-free survival versus dual therapy in resistant CLL.
news.gmj.ge
September 29, 2026 at 9:27 AM
danafarber.bsky.social
Jorge Castillo, MD, shares data on an all-oral, non-chemo, fixed-duration regimen for Waldenström macroglobulinemia using pirtobrutinib and venetoclax. The combination delivered rapid, profound and 100% overall responses with manageable side effects and high rate of deep responses. #ASH25
December 6, 2025 at 7:34 PM
onclive.bsky.social
🇨🇳China's NMPA has approved of pirtobrutinib in treatment-naive and previously treated CLL/SLL, based on the phase 3 BRUIN CLL-313 and BRUIN CLL-314 trials.

Full details 💥: onclive.com/view/china-s...

#leusm #oncology
China's NMPA Approves Pirtobrutinib Across CLL | OncLive
The NMPA has approved of pirtobrutinib in treatment-naive and previously treated CLL/SLL.
onclive.com
September 28, 2026 at 6:54 PM
danafarber.bsky.social
The second day of poster presentations at #ASH25 featured research ranging from venetoclax and pirtobrutinib in relapsed/refractory Waldenström's macroglobulinemia to spatial proteomics of the bone marrow.
December 7, 2025 at 11:53 PM
ecancer.org
At #EHA2026, Matthew Davids, MD, MMSc discusses phase 3 BRUIN CLL 322 results showing fixed-duration pirtobrutinib plus venetoclax and rituximab improved PFS vs SoC in previously treated CLL/SLL. Watch his interview👉https://bit.ly/4xYnE3x #CLL #Haematology #Oncology
Pirtobrutinib plus venetoclax rituximab improves PFS in previously treated CLL and SLL - ecancer
Dr Matthew Davids speaks to ecancer about results from the phase 3 BRUIN CLL 322 trial evaluating fixed-duration pirtobrutinib, a noncovalent BTK inhibitor, in
bit.ly
August 13, 2026 at 11:27 AM
fintwitter.bsky.social
LILLY'S JAYPIRCA (PIRTOBRUTINIB) SIGNIFICANTLY EXTENDED PROGRESSION-FREE SURVIVAL WHEN ADDED TO A VENETOCLAX TIME-LIMITED REGIMEN IN PATIENTS WITH PREVIOUSLY TREATED CLL/SLL
April 13, 2026 at 10:51 AM
drmiguelperales.bsky.social
#ash25 potentially practice changing results in frontline Rx of CLL - impressive PFS with pirtobrutinib vs BR 1/2
December 9, 2025 at 1:14 PM
leukaemiauk.bsky.social
📢 Today, NICE has recommended Pirtobrutinib for eligible people with chronic lymphocytic leukaemia (CLL) on the NHS in England.

This provides another targeted treatment option for people whose CLL has returned or stopped responding after treatment with a BTK inhibitor. 👏
An orange graphic which reads, ‘New treatment for chronic lymphocytic leukaemia in England: Pirtobrutinib’ followed by ‘Approved’ with a green tick symbol.
July 1, 2026 at 10:35 AM
agentictribune.bsky.social
Pirtobrutinib Triplet Prolongs Progression-Free Survival in Previously Treated CLL, Lancet Reports

#cancer #cll #hematology #pirtobrutinib
Pirtobrutinib Triplet Prolongs Progression-Free Survival in Previously Treated CLL, Lancet Reports
Phase 3 BRUIN CLL-322 found fixed-duration pirtobrutinib with venetoclax–rituximab cut progression/death risk by ~45% vs venetoclax–rituximab in relapsed CLL.
agentictribune.com
July 9, 2026 at 10:34 PM
onclive.bsky.social
📈 Responses were shown in patients with R/R CLL who had received both a covalent BTK inhibitor and a BCL2 inhibitor, according to a pooled analysis of BRUIN trials.

Read more here ➡️: www.onclive.com/view/pirtobr...

#SOHO2026 #leusm #oncology @societyofhemonc.bsky.social
Pirtobrutinib Elicits Responses After Covalent BTK Inhibitor Failure in R/R CLL | OncLive
Strong overall response rates with pirtobrutinib in relapsed/refractory CLL previously treated with covalent BTK inhibitors were shown in a pooled analysis.
www.onclive.com
September 14, 2026 at 8:45 PM
anand-88-patel.bsky.social
Day 7 - pirtobrutinib in Richter transformation

www.thelancet.com/journals/lan...
August 11, 2025 at 12:07 AM
iocbprague.bsky.social

#evolution #veda #science
#research #pirtobrutinib

Direct Multi-Deuterium Labelling of Pirtobrutinib (Marek) - Journal of Labelled Compounds and Radiopharmaceuticals: doi.org/10.1002/jlcr...

@iocbprague.bsky.social
July 19, 2024 at 12:23 PM
onclive.bsky.social
Pirtobrutinib Earns Positive CHMP Opinion for R/R CLL After a Covalent BTK Inhibitor

www.onclive.com/view/pirtobr...
Pirtobrutinib Earns Positive CHMP Opinion for R/R CLL After a Covalent BTK Inhibitor
The CHMP has recommended the European approval of pirtobrutinib for relapsed/refractory CLL previously treated with a covalent BTK inhibitor.
www.onclive.com
February 28, 2025 at 5:09 PM
gmj-georgia.bsky.social
Triple combination therapy with pirtobrutinib, venetoclax, and rituximab extends survival in resistant CLL patients.

https://news.gmj.ge/briefs/triple-drug-combination-shows-promise-for-resistant-chronic-lymphocytic-leukemia/
Triple-Drug Combination Shows Promise for Resistant Chronic Lymphocytic Leukemia
Triple combination therapy with pirtobrutinib, venetoclax, and rituximab extends survival in resistant CLL patients.
news.gmj.ge
September 22, 2026 at 9:27 AM
4040rec.bsky.social
#NICE #chroniclymphocyticleukaemia #CLL #leukaemia #NICEdraftguidance #CLLpatients #pirtobrutinib #Jaypirca #EliLilly #relapsedCLL #refractoryCLL #tabletathome #hospitalvisits #Pirtobrutinib #NICEdraftrecommendation #Brutonstyrosinekinaseinhibitor #BTKinhibitor #BTKinhibitortreatment
zurl.co/UoNBb
New take at home drug recommended for people with chronic lymphocytic leukaemia
www.nice.org.uk
April 20, 2026 at 10:40 AM
onclive.bsky.social
First-Line Pirtobrutinib Plus Venetoclax/Obinutuzumab Generates High uMRD Rates in CLL @ash-hematology.bsky.social #ASH24 #leusm #oncology www.onclive.com/view/first-l...
First-Line Pirtobrutinib Plus Venetoclax/Obinutuzumab Generates High uMRD Rates in CLL
First-line pirtobrutinib plus venetoclax and obinutuzumab generated high uMRD6 remission rates among patients with chronic lymphocytic leukemia.
www.onclive.com
December 10, 2024 at 9:48 PM
oncologynurseadv.bsky.social
Topline data were announced from a phase 3 trial evaluating pirtobrutinib in treatment-naïve patients with chronic lymphocytic leukemia or small lymphocytic lymphoma without 17p deletions.

https://bit.ly/48Jk4k3

#lymsm
Pirtobrutinib Improves PFS in Treatment-Naïve CLL/SLL Patients - Oncology Nurse Advisor
Pirtobrutinib is currently approved for the treatment of patients with CLL/SLL who have received at least 2 prior lines of therapy.
bit.ly
October 5, 2025 at 6:55 PM
fintwitter.bsky.social
Eli Lilly and Co's Jaypirca (Pirtobrutinib) shows significant improvement in progression-free survival for chronic lymphocytic leukemia and small lymphocytic lymphoma patients in a Phase 3 study. The overall survival trend favors Pirtobrutinib. 🩺
September 8, 2025 at 10:46 AM
4040rec.bsky.social
#oncology #Lilly #LillyOncology #Jaypirca #Pirtobrutinib #primaryendpoint #EliLilly #CLL313 #CLL314 #phase3 #BRUINCLL314trial #chroniclymphocyticleukaemia #CLL #smalllymphocyticlymphoma #SLL #noncovalentBTKinhibitor #Imbruvica #ibrutinib #covalentBTKinhibitor
pharmatimes.com/news/lillys-...
Lilly’s Jaypirca shows positive results in phase 3 trial - PharmaTimes
Pirtobrutinib meets primary endpoint in CLL/SLL study
pharmatimes.com
September 9, 2025 at 10:14 AM
theaacr.bsky.social
The @fda.gov granted traditional approval to the BTK inhibitor pirtobrutinib for certain previously treated adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: buff.ly/rHyJoSQ
FDA grants traditional approval to pirtobrutinib for chronic lymphocyt
On December 3, 2025, the Food and Drug Administration granted traditional approval to pirtobrutinib (Jaypirca, Eli Lilly and Company) for adults with relapsed o
www.fda.gov
December 3, 2025 at 10:53 PM
drmiguelperales.bsky.social
#ash25 share.google/Lzvrr9xoFFTk...
Pirtobrutinib Superior to BR in First-Line CLL/SLL: BRUIN CLL-313 Results | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Pirtobrutinib shows significant improvement in progression-free survival for untreated CLL/SLL, potentially setting a new standard of care.
share.google
December 9, 2025 at 1:05 PM
ashclinicalnews.bsky.social
#ASH25 In the first head-to-head study of the two drugs, #pirtobrutinib was found to produce ORRs that were noninferior to those seen with #ibrutinib in both the intent-to-treat and R/R population of patients with #CLL: https://ow.ly/WIEg50XExWA
#HemeSky #OncSky
December 7, 2025 at 8:30 PM
rcatanho.bsky.social
Pirtobrutinib, inhibidor no covalente de la BTK, agregado a venetoclax más rituximab prolonga la supervivencia libre de progresión en pacientes con leucemia linfocítica crónica firstwordpharma.com/story/7179946
firstwordpharma.com
April 14, 2026 at 7:50 AM
newsen.bsky.social
Eli Lilly's Jaypirca Shows Breakthrough Results for CLL/SLL Patients in Clinical Trial#USA#Indianapolis#Eli_Lilly#CLL#Jaypirca
Eli Lilly's Jaypirca Shows Breakthrough Results for CLL/SLL Patients in Clinical Trial
New Phase 3 trial results demonstrate that Jaypirca (pirtobrutinib) significantly improves outcomes for patients with relapsed CLL/SLL when combined with venetoclax.
third-news.com
June 14, 2026 at 7:23 AM
karluchipa.bsky.social
Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

pubmed.ncbi.nlm.nih.gov/41353787/

So far so good (for patients), but not so much for progress in the art of readable writing. #Medsky
Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma - PubMed
Pirtobrutinib demonstrated NI of ORR versus ibrutinib, with a favorable early PFS trend, particularly in TN patients, and a favorable safety profile including low rates of atrial fibrillation and hypertension.
pubmed.ncbi.nlm.nih.gov
December 16, 2025 at 9:27 AM